This has been particularly the case for breast cancer, and our own group has performed several DC-based vaccine clinical trials for HER-2pos breast cancer [20,37,38,39] using promiscuous HLA class II binding HER-2 peptides [38,40] as immunogens. Here, ERBB2 is linked to breast cancer.